BMS Archive

Fungi · Scientific monograph

Xylaria nigripes

Wu Ling Shen

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: CNS Depression Research, Neurological & Cognitive Research, Oxidative Stress Research

Research overview

Historical use

Known in Traditional Chinese Medicine as 'Wu Ling Shen' (the fungus found inside the chambers of ancient termite mounds). Used historically for insomnia, anxiety, and to calm the mind. Referenced in TCM pharmacopeias as a sedative tonic. Grows inside the nests of Odontotermes formosanus (Formosan subterranean termite) in a unique symbiotic relationship.

Modern research context

Studied primarily for sedative, anxiolytic, and neuroprotective properties; metabolites, biological activities, and clinical applications have been comprehensively reviewed [1]. A multicenter randomised controlled trial documented significant antidepressant effects in epilepsy patients receiving X. nigripes extract alongside standard therapy [2]. Anti-inflammatory polysaccharide fractions exhibit synergistic activity in vitro [3]. Novel resorcinol derivatives [4] and sesquiterpenoids [5] with neuroprotective activities have been isolated from the fruiting body. Commercial preparations are marketed in Taiwan and China for insomnia and anxiety, though broader clinical data remain limited [1].

Adverse effects

Insufficient human clinical data. Potential sedation and CNS depression. No significant toxicity reported in preclinical studies.

Contraindications

CNS depressants (benzodiazepines, alcohol, barbiturates, opioids) — potential additive sedation. Caution when operating machinery. Insufficient data for comprehensive contraindication profile.

Clinical and phytochemical data

Used part

Sclerotium found inside termite mounds

Primary active compounds

  • N/A — specific active compounds not yet fully characterised

  • GABA-modulating constituents (chemical identity not established)

  • Polysaccharides

  • Phenolic compounds

Mechanism of action

Positive allosteric modulation of GABA-A receptor (benzodiazepine-like effect), prolonging inhibitory chloride channel opening. 5-HT reuptake inhibition proposed in animal models. Anti-inflammatory effects via NF-κB inhibition and reduction of IL-6, TNF-α. Adenosine receptor modulation may contribute to anxiolytic and sleep-promoting effects.

Pharmacokinetics

Absorption

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — No human PK data available. Bioavailability of active constituents not characterised.

Distribution

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Active alkaloids and sesquiterpenes are lipophilic; cross the blood-brain barrier in animal studies and distribute broadly to CNS, with preference for limbic structures (amygdala, hippocampus). No formal human PK distribution data; all data from rodent sleep and anxiety models.

Metabolism

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Not established.

Excretion

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Not established.

Safety and interactions

Drug interactions

CNS depressants — additive sedative effect (theoretical, based on GABA-A mechanism). Alcohol — potential potentiation of CNS depression. No drug interaction studies in humans.

Toxicity

LD50 not established for human use. Preclinical animal studies show no significant organ toxicity at doses up to 5 g/kg. Human safety data absent.

Special precautions

Pregnancy

Insufficient data. Avoid during pregnancy.

Lactation

Insufficient data. Avoid during breastfeeding.

Hepatic impairment

No clinical data are available in hepatic impairment. No hepatotoxicity has been identified in preclinical studies. The GABA-A modulating activity of nigrigenin may theoretically be potentiated in hepatic encephalopathy due to altered GABAergic tone; use with caution and standard monitoring.

Renal impairment

No clinical data are available in renal impairment. No specific nephrotoxicity has been identified in preclinical studies. Standard monitoring is recommended; renal excretion pathway for nigrigenin metabolites has not been characterised.

Sources and references

  1. [1] - Liang AL., "A comprehensive review of the metabolites, biological activities, and clinical application of Xylaria nigripes.", J Ethnopharmacol, 2025, PMID: 40436127
  2. [2] - Peng WF., "The anti-depression effect of Xylaria nigripes in patients with epilepsy: A multicenter randomized controlled study.", Seizure, 2015, PMID: 26076841
  3. [3] - Jen CI., "Synergistic anti-inflammatory effects of different polysaccharide components from Xylaria nigripes.", J Food Biochem, 2021, PMID: 33687093
  4. [4] - Li LQ., "Four new resorcinol derivatives with neuroprotective activities from Xylaria nigripes.", Nat Prod Res, 2022, PMID: 33715538
  5. [5] - Long HP., "Five brasilane-type sesquiterpenoids with neuroprotective activities from Xylaria nigripes.", Phytochemistry, 2025, PMID: 39662694

Additional source links

Continue browsing